Quantcast

Latest Blinatumomab Stories

2014-12-06 16:21:05

- Data shows 36 of 39 pediatric patients with relapsed/refractory acute lymphoblastic leukemia (r/r ALL) (92%) experienced complete remissions[1] EAST HANOVER, N.J., Dec.

2014-10-15 16:30:25

- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191 EAST

2011-04-28 12:02:00

ROCKVILLE, Md., April 28, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART(TM) antibody technology. Included in the peer-reviewed article titled, "Application of...

2010-06-29 07:30:00

BETHESDA, Md., June 29 /PRNewswire-FirstCall/ -- Micromet, Inc.

2010-06-14 07:30:00

BETHESDA, Md., June 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI) today announced the presentation of updated results from a Phase 1 trial of the Company's lead product candidate blinatumomab (MT103) in patients with relapsed non-Hodgkin's lymphoma (NHL).

2010-06-08 07:00:00

BETHESDA, Md., June 8 /PRNewswire-FirstCall/ -- Micromet, Inc.


Word of the Day
dwale
  • The deadly nightshade, Atropa Belladonna, which possesses stupefying or poisonous properties.
  • A sleeping-potion; a soporific.
  • To mutter deliriously.
The word 'dwale' comes from an Old English word meaning 'error, doubt, delusion.'
Related